Region:North America
Author(s):Geetanshi
Product Code:KRAC4540
Pages:100
Published On:October 2025
By Type:The market is segmented into various types of biomarkers, including Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, and Epigenetic Biomarkers. Among these, Genetic Biomarkers currently lead the market in terms of revenue, driven by their widespread use in precision medicine and the increasing availability of advanced genomic testing platforms. Protein Biomarkers remain critical for disease diagnosis and monitoring, particularly in oncology and cardiovascular diseases, while Cell-Based Biomarkers are the fastest-growing segment due to innovations in liquid biopsy and single-cell analysis technologies. The focus on precision medicine and the development of targeted therapies continue to drive demand across all biomarker types.
By Application:The applications of blood-based biomarkers include Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Metabolic Disorders, and Others. Oncology is the leading application area, driven by the increasing incidence of cancer and the need for early detection and personalized treatment options. The growing adoption of liquid biopsies and advancements in biomarker discovery are also contributing to the dominance of oncology in this segment. Cardiovascular diseases represent another major application, supported by the rising burden of heart disease and the development of novel cardiac biomarkers. Neurological and metabolic disorders are emerging areas, with increasing research into biomarkers for Alzheimer’s disease, diabetes, and other chronic conditions.
The US Blood Based Biomarkers Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN N.V., Illumina, Inc., Myriad Genetics, Inc., Guardant Health, Inc., Exact Sciences Corporation, Genomic Health, Inc., Luminex Corporation, Veracyte, Inc., Foundation Medicine, Inc., Biocept, Inc. contribute to innovation, geographic expansion, and service delivery in this space.
The future of the US blood-based biomarkers market appears promising, driven by technological advancements and a growing emphasis on personalized healthcare. As non-invasive testing methods gain traction, the integration of artificial intelligence in biomarker discovery is expected to enhance diagnostic accuracy. Furthermore, the increasing focus on multi-omics approaches will likely lead to more comprehensive biomarker profiles, improving patient outcomes and fostering innovation in the industry. These trends indicate a dynamic and evolving market landscape.
| Segment | Sub-Segments |
|---|---|
| By Type | Genetic Biomarkers Protein Biomarkers Metabolic Biomarkers Cell-Based Biomarkers Epigenetic Biomarkers |
| By Application | Oncology Cardiovascular Diseases Infectious Diseases Neurological Disorders Metabolic Disorders Others |
| By End-User | Hospitals Diagnostic Laboratories Research Institutions Pharmaceutical Companies Others |
| By Distribution Channel | Direct Sales Distributors Online Sales Others |
| By Region | Northeast Midwest South West Others |
| By Technology | Next-Generation Sequencing Polymerase Chain Reaction (PCR) Mass Spectrometry ELISA Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Oncology Biomarker Testing | 120 | Oncologists, Pathologists |
| Cardiovascular Biomarkers | 80 | Cardiologists, Clinical Researchers |
| Infectious Disease Biomarkers | 60 | Infectious Disease Specialists, Laboratory Technicians |
| Diabetes Management Biomarkers | 50 | Endocrinologists, Diabetes Educators |
| General Healthcare Providers | 70 | General Practitioners, Family Medicine Doctors |
The US Blood Based Biomarkers Market is valued at approximately USD 3 billion, reflecting significant growth driven by advancements in diagnostic technologies, the increasing prevalence of chronic diseases, and a focus on personalized medicine.
What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.
